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The 12th workshop on 'Mechanisms In B-cell Neoplasia' was held In 
Bethesda. MD, in June 1994. organised mainly by Dr. Alan Rabson at 
the NatIOnal Cancer Institute. A book In the Current TopIcs in 
MicrobIOlogy and Immunology (CTMI) series (number 194) report 
from this meetIng. edited by Michael Potter and Fntz Melchers. 
The maIn tOpICS covered were multiple myeloma (MM) 
plasmocytoma. human and mome B-cell lymphomas. growth 
regulatIOn OL-6. c-myC'. Bcl-'2. cyclin DI and ABU and genomic 
instability 
MM. which IS becoming a more common malignant disease. was 
discussed from many different aspects. IncludIng pre-myeloma cells. 
expreSSIng an Ig Idiotype. as Initially desCrIbed by Mellstedt et al (ClIn. 
Exp. ImmunoI.. 17. 371. 1974). The~e cells were Invesligated by more 
sensitive techmques for clonality. IncludIng PCR and DNA 
fingerprintIng. These pre-myeloma cells caused a problem In 
autologous bone-marrow transplantatIOn. due to their ill-defined 
phenotype marker expressIOn In relatIOn to CD34 expression. An even 
earlier stage of MM may relate to a conditIOn called Monoclonal 
Oamopath) of Undetermined Slgmficance (MOUS). ocurrIng of 3% of 
the population over 70 years of age. A large percentage of these MOUS 
patients were reported to develop Into MM. Surface Ig on pre-myeloma 
cells may bInd autoantigens and thereby upregulate surt~\Ce molecules 
involved In B cell activatIOn and differentiation. 
The deregulatIOn of C-III)'C IS Important in many types ofB cell tumors 
In relation to the cellular control of mitotic cycling and apoptosis. Myc. 
and myc heterodlmers. bInd to regulator) motifs in DNA and thus 
regulate the expressIOn of dliTerent genes An Increase In c-!nrc also 
leads to the accumulatIOn of cells In 0 liS for further progressIOn to 
death by apoptosls. 
IL-6 was Implicated as a growth and maturation factor for plasma 
cell tumors. IL-6 was found to activate different transduction pathways 
induding Immediate JAK-STAT and delayed. yus-dependent kmases 
and CD40-dependent signalling may Induce autocrine IL-6 productIOn 
B cell regulatIOn by IL-6 Illustrate the complexity of signalling by 
cytokines that can modulate transcriptional factors important for 
termInal differentiation. The importance of IL-6 bIndIng to the IL-6 
receptor and signal transducer was approached by Isolating a soluble 
form of the IL-6 receptor (sIL-6R) and an lysIng the effect of other 
growth factors that share the same signal transducer (gpI30). 
Oenomic Instability was studied in relation to VDJ rearrangement;,. 
and heavy chaIn Isotope switchIng. and the translocatIOn of other. 
non-Ig regIOns. includIng target genes. such as c-myc. Bcl-'2. pl't-l and 
others. The PCR technique was used to further charactense 
chromosomal translocatlOns in relatIOn to the natural history of 
lymphoma developmcnt and the IdentificatIOn of some of these also In 
non-neoplastic tissues. 
Orowth regulation by the Bcl-'2 gene family was discussed. 
HeterodlmenzatlOn With Bax was presented as a possible mechamsm 
for BcI-'2 to repress cell death. This Information needs only to be 
completed With the latest descnptlOns of other survival genes. such a, 
BAG-I and Bud (Takayama et a!.. Cell 80:'229 and Yang et al. Cell 
80.285). Bcl-'2 overexpres;,lOn In B-CLL IS assOCiated With Increased 
accumulatIOn of B-CLL cells and apoptosls InhibitIOn BcI-2 was 
proposed to regulate calcIUm release and to have antIOxidant actIVIty 
to explain its protective potential agaInst different conditIOn;, that 
Induce apoptosls 
These are Just a few of the many reports (54) written by leadlllg 
workers m the field. The book focuses on important. 'hot' areas m 
mechamsms In B-cell neoplaSia and IS a nch ;,ource of informatIOn both 
for climcal and baSIC SClcntlst, 
M.loudal 
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Alzhelmer\ disease (AD) IS major cause of dementia. and a major 
health problem, With suffenng both for the affected and their relatives. 
and enormous costs for the society. The last years have also seen a 
weaIth of studies to charactense the neurochemical pathology of AD. 
ThiS knowledge forms the platform for therapeutic strategies and 
attempts to develop ne", drugs for the disorder. Indeed. AI::helmer 
DIsease TherapeutIc Strategies. the third publication in a senes on 
Alzheimer therapy. edited by Olacobmi and Becker. gives a welcome 
extensive update on these tOpiCS. 
The chohnergic hypothesis still has a central role m AD therapeutics. 
receIVIng almost half the space in the book. The leadmg therapeutic 
approach almmg at mcreasing cholmerglc neurotransmlsslon in AD IS 
by means of cholinesterase mhlbltor (ChEll. Indeed. the only registered 
compound for treatment of the cogmtlve symptoms m AD is a ('hEr. 
namely tetrahydroammoacndIne. or tacrine. Although 13 chapters go 
through ChEIs. also other compounds almmg at enhancing the 
cholinergic system are covered. mcluding several chapters on mcotinic 
and muscanmc agomsts. 
However. a IS clear that multiple neurotransmitter systems are 
disturbed in AD One of these IS the serotonmerglC system, reViewed 
In the chapter by Oottfnes. Patients with AD suffer not only from 
memory disturbances and other cogmtlve symptoms. but abo from 
emotIOnal disturbances Treatment wah selective serotomn re-uptake 
mhlbltors. such as cltalopram. reduce emotIOnal disturbances such as 
IrrItability. anxiety. and depreSSIOn These symptoms may. in the earlier 
stages of the disorder. often cause more discomfort than the cognitive 
symptoms. 
Other therapeutIC approaches m AD mcludes nootroplc. antiOXidant 
and antl-mflammatory agents. In the chapters by McOeer and co-
workers and by Webster and Rogers. evidence for an inflammatory 
component m the pathogeneSIs IS reViewed Interestmgly. also a 
prelimInary climcal tnal usmg the non-sterOidal anti-Inflammatory 
drug mdomethacm. support that anti-inflammatory agents may be 
benefiCial for the treatment of AD. 
Several chapters discuss therapeutic strategies aImmg at arresting the 
deposition of amyloid is the bram. The pros and cons concerning the 
amylOid cascade hypothesis are weighed In the chapter by Hardy and 
Duff. Accordmg to the hypotheSIS. fJA4 protem depOSitIOn IS the central 
event m the pathogeneSIs of AD. which IS regarded an amylOid storage 
disease of the brain Amyloid depOSitIOn IS regarded to start a cascade 
of events that finally results in the dementia that bnngs the patient to 
the phYSICian. The essential predictIOn In the amylOid cascade 
hypotheSIS IS that fJA4 protem. or aggregates of fJA4 protem. IS 
neurotoxIc. ThiS has been both ntenslvely tested (m ammal 
expenments and cell culture systems). and debated (In a whole Issue of 
Neurobiology of Agmg) In fact. a book on therapeutic strategies tor 
AD IS an excellent forum to diSCUSS the amylOid cascade hypotheSIS. 
smce the real challenge for the amylOid cascade hypotheSIS Will not 
come untlll drugs that (In cell culture or ammal models) arrest amylOid 
depOSitIOn can be tested In IIvmg patients with AD. to sec If they also 
arrest the progressIOn of the disease. 
Nine chapters are devoted to the issue of momtonng the drug by 
different Imagmg techmques (e g. SPECT and PET) and by climcal 
testing (using different rating scales). However. although eVidence are 
accumulatmg that what today IS called 'Alzheimer's disease' actually IS 
a heterogeneous syndrome. no chapter diSCUSS whether the drug effect 
may vary between AD patients With different aetIOlogy (e g rare genetIC 
forms vs. common sporadiC forms) and pathogeneSIs (e.g. patients With 
or Without nsk-factors such as the ApoE4 allele or concomitant 
vascular diseases). Moreover. It IS also logical to as;,ume that the 
pathogeneSIs In the rare cases With early-onset sporadiC AD (wIth onset 
40- 65 years of age) IS not Identical to that In elderly patients 80 90 years 
of age (where AD pathology IS found In almost all mdmduals. and 
25-40% has dementia). Thus. also the chmcal response to different 
drugs may vary between these patients ConseLJuently. a chl1lcal 
